Germany: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

European Biosimilar Updates – Formycon's Ustekinumab And Alvotech's Cetrolizumab Pegol

On June 26, 2025, Formycon AG ("Formycon") announced a distribution agreement with Teva Group subsidiary Ratiopharm GmbH ("Ratiopharm") for the semi-exclusive commercialization...

Germany Healthcare

GP

Goodwin Procter LLP

EU Commission Consultation On High-Risk AI Systems: Key Points For Life Sciences And Health Care

On 6 June 2025, the European Commission launched a targeted stakeholder consultation on the classification and regulation of high-risk artificial intelligence (AI) systems under the EU Artificial Intelligence Act (AI Act).

European Union Healthcare

GT

Greenberg Traurig, LLP

Second Medical Use Claims In The UPC System: Prerequisites And Mechanism Of Examination For Infringement

The Local Division of Düsseldorf is the first UPC panel to set out the prerequisites and establish essential factors for assessing infringement of second medical use claims in the UPC system. Its approach builds on the criteria developed by national (German) courts.

Germany Healthcare

BP

Bardehle Pagenberg

New German Government: Key Plans For The Life Sciences And Healthcare Sector

Following the election in February, the party leaderships of CDU, CSU and SPD have agreed on a coalition agreement titled "Responsibility for Germany".

Germany Healthcare

AO

A&O Shearman

New CJEU Ruling On The Borderline Between Medicinal Products And Medical Devices: Key Takeaways

Germany Healthcare

AO

A&O Shearman

Wind Of Change - Are Medical Sick Leave Certificates Still Untouchable?

Germany Healthcare

L

Littler

Key Regulatory Changes Impacting The Healthcare Industry In The EU And Germany In 2025

European Union Healthcare

AO

A&O Shearman

Council Approves EU Packaging Regulation ‒ Introduction Of Standardised Legal Framework For Entire Packaging Life Cycle And New Challenges For Market Participants

Germany Healthcare

N

Noerr

The Digital Act: A Boost For Digitalisation In German Healthcare

Germany Healthcare

GL

Gleiss Lutz

Bundestag Debates Government Bill On Medicines Shortage

Germany Healthcare

GL

Gleiss Lutz

Germany As A Location For Pharmaceutical Businesses - Quo Vadis, 2024?

Germany Healthcare

TW

Taylor Wessing PartG mbB

Trademark Protection In The Life Sciences Business - Why Start-Ups And Founders Should Take Care

Germany Healthcare

TW

Taylor Wessing PartG mbB

OLG Nuremberg On The Unjustified Accusation Of Abuse Of Rights In The Case Of A Warning Letter

Germany Healthcare

TW

Taylor Wessing PartG mbB

OLG Hamburg On The Inadmissibility Of Issuing Pharmaceutical Prescriptions Over The Internet

Germany Healthcare

TW

Taylor Wessing PartG mbB

Transfer Pricing And Customs Valuation: Navigating Germany's Regulatory Landscape In 2025

N

NERA

Alvarez & Marsal Webinar: European Restructuring And Corporate Distress In 2025 (Video)

Germany Insolvency

AM

Alvarez & Marsal

Investment Management Client Alert September 2025

Germany Commercial

KG

K&L Gates LLP

From Sustainability To Defense: What's The Impact On The Real Estate Sector In Germany?

Germany Real Estate

AO

A&O Shearman

SOC-reports: Building Trust Through Audited Internal Controls

Germany Accounting

Boege Rohde Luebbehuesen

See more

Food and Drugs Law

Herbert Smith Freehills Kramer Comments For LSIPR On Small Molecule Litigation In The UPC

Life sciences-related cases started at a low level during the first years of the UPC's existence (about 25% of cases) and focused initially on the medtech sector.

KL

Herbert Smith Freehills Kramer LLP

Second Medical Use Claims At The UPC: What Are The Infringement Prerequisites And Legal Standards? (Video)

The Düsseldorf Local Division has recently issued a decision of considerable importance in the pharmaceutical field: the first decision in the UPC system dealing with second medical use claims.

BP

Bardehle Pagenberg

European Biosimilar Updates – Formycon's Ustekinumab And Alvotech's Cetrolizumab Pegol

On June 26, 2025, Formycon AG ("Formycon") announced a distribution agreement with Teva Group subsidiary Ratiopharm GmbH ("Ratiopharm") for the semi-exclusive commercialization...

Germany Healthcare

GP

Goodwin Procter LLP

Second Medical Use Claims In The UPC System: Prerequisites And Mechanism Of Examination For Infringement

Germany Healthcare

BP

Bardehle Pagenberg

New German Government: Key Plans For The Life Sciences And Healthcare Sector

Germany Healthcare

AO

A&O Shearman

New CJEU Ruling On The Borderline Between Medicinal Products And Medical Devices: Key Takeaways

Germany Healthcare

AO

A&O Shearman

Key Regulatory Changes Impacting The Healthcare Industry In The EU And Germany In 2025

European Union Healthcare

AO

A&O Shearman

Council Approves EU Packaging Regulation ‒ Introduction Of Standardised Legal Framework For Entire Packaging Life Cycle And New Challenges For Market Participants

Germany Healthcare

N

Noerr

More Pills To Swallow – Antitrust Scrutiny In The Pharmaceutical Sector Remains High

European Union Anti-trust

HM

Hengeler Mueller

See more

Life Sciences, Biotechnology & Nanotechnology

LD Hamburg, October 21, 2025, Order In The Proceedings For Provisional Measures, UPC_CFI_553/2025

To establish jurisdiction, at least the plausible allegation of infringing acts in the country in question is necessary.

BP

Bardehle Pagenberg

Herbert Smith Freehills Kramer Comments For LSIPR On Small Molecule Litigation In The UPC

Life sciences-related cases started at a low level during the first years of the UPC's existence (about 25% of cases) and focused initially on the medtech sector.

KL

Herbert Smith Freehills Kramer LLP

European Biosimilar Updates – Formycon's Ustekinumab And Alvotech's Cetrolizumab Pegol

On June 26, 2025, Formycon AG ("Formycon") announced a distribution agreement with Teva Group subsidiary Ratiopharm GmbH ("Ratiopharm") for the semi-exclusive commercialization...

Germany Healthcare

GP

Goodwin Procter LLP

Nordic-Baltic Regional Division, July 21, 2025, Decision In First Instance, UPC_CFI_380/2023

BP

Bardehle Pagenberg

Konsultation der EU-Kommission zu Hochrisiko-KI-Systemen: Kernpunkte für den Life Sciences- und Health Care-Sektor

Germany Technology

GT

Greenberg Traurig, LLP

EU Commission Consultation On High-Risk AI Systems: Key Points For Life Sciences And Health Care

European Union Healthcare

GT

Greenberg Traurig, LLP

Second Medical Use Claims In The UPC System: Prerequisites And Mechanism Of Examination For Infringement

Germany Healthcare

BP

Bardehle Pagenberg

New German Government: Key Plans For The Life Sciences And Healthcare Sector

Germany Healthcare

AO

A&O Shearman

New CJEU Ruling On The Borderline Between Medicinal Products And Medical Devices: Key Takeaways

Germany Healthcare

AO

A&O Shearman

See more

Healthcare

Second Medical Use Claims At The UPC: What Are The Infringement Prerequisites And Legal Standards? (Video)

The Düsseldorf Local Division has recently issued a decision of considerable importance in the pharmaceutical field: the first decision in the UPC system dealing with second medical use claims.

BP

Bardehle Pagenberg

Konsultation der EU-Kommission zu Hochrisiko-KI-Systemen: Kernpunkte für den Life Sciences- und Health Care-Sektor

Am 6. Juni 2025 hat die Europäische Kommission eine Konsultation zur Einstufung und Regulierung von Hochrisiko-KI-Systemen im Rahmen der...

Germany Technology

GT

Greenberg Traurig, LLP

EU Commission Consultation On High-Risk AI Systems: Key Points For Life Sciences And Health Care

On 6 June 2025, the European Commission launched a targeted stakeholder consultation on the classification and regulation of high-risk artificial intelligence (AI) systems under the EU Artificial Intelligence Act (AI Act).

European Union Healthcare

GT

Greenberg Traurig, LLP

New German Government: Key Plans For The Life Sciences And Healthcare Sector

Germany Healthcare

AO

A&O Shearman

Wind Of Change - Are Medical Sick Leave Certificates Still Untouchable?

Germany Healthcare

L

Littler

Key Regulatory Changes Impacting The Healthcare Industry In The EU And Germany In 2025

European Union Healthcare

AO

A&O Shearman

LD Düsseldorf, September 6, 2024, Order Of The Court Of First Instance, UPC_CFI_165/2024 And UPC_CFI_166/2024

BP

Bardehle Pagenberg

ECJ Clarifies Further Questions On Compensation For Damages And Health Data

Germany Privacy

HK

HEUKING

The Digital Act: A Boost For Digitalisation In German Healthcare

Germany Healthcare

GL

Gleiss Lutz

See more

Latest Videos

See more

Healthy Byte | Live From HIMSS 25! (Video)

AB

Alston & Bird

Ile Wynosi Zadłużenie Szpitali?

KHG Hupajlo Grzegorczyk & Partners

Lex Inside - L'Actualité Juridique - Émission Du 28 Juin 2024 (Video)

J

Jeantet

Episode #12 | European Health Data Space Regulation | 1 December 2022 (Video)

AM

Arendt & Medernach

What Regulatory Challenges Are Facing The Life Sciences Sector? (Video)

WF

William Fry

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More